According to Report, the Clinical Trial Supplies market size is estimated to surpass around US$ 13.3 billion by 2030 and is expected to registered growth at a CAGR of 17.3% from 2021 to 2030.
According to Report, the Clinical Trial Supplies market size is estimated to surpass around US$ 13.3 billion by 2030 and is expected to registered growth at a CAGR of 17.3% from 2021 to 2030.
Growth Factors
The Increasing volume of clinical trial studies coupled with the growing complexity in conduction of these trials are the primary driver of the industry. Furthermore, geographic expansion and development of Information Technology (IT) to facilitate higher integration and smooth performance of activities are other vitally impacting parameters. Over the next eight years, the clinical trials and pharmaceutical industry is anticipated to continue steady growth, thereby promoting the high requirement of clinical trial supplies.
Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/37892
U.S and Canada are home to majority of clinical trials which are conducted in this region. No language barrier is one of the major factor for the preference of this region for majority of clinical trials, as English language is widely spoken in this region. Major CRO’s and biopharmaceutical companies have their hub in this region and with advancement in technology the demand for efficient supplies are increasing and the region is expected to dominate the clinical trial supplies market over the forecast period.
| Report Coverage | Details |
| Market Size | US$ 13.3 billion by 2030 |
| Growth Rate | CAGR of 17.3% From 2021 to 2030 |
| Base Year | 2020 |
| Historic Data | 2017 to 2020 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Clinical Phase, Product &Service, End-Use, Therapeutic Use, |
| Regional Scope | North America, Latin America, Europe, Asia Pacific, MEA |
| Companies Mentioned | Almac Group; Biocair; Catalent, Inc.; KLIFO; Movianto (Walden Group); PCI Pharma Services; Sharp; Thermo Fischer Scientific, Inc.; Marken; Parexel International Corporation |
Report Highlights
Phase I is expected to be the fastest growing segment due to rise in number of outsourced Phase I trials. Lesser sample population and high capital investment are the major factors responsible for outsourcing the major volume of these trials. It has been identified that about 54.0% of Phase I trials are outsourced and the number is expected to increase owing to globalization of these trials.
Phase III trials process is characterized to possess a high level of complexity compared to all others. Although, the number of drugs in this phase is comparatively low, the complexity associated with this phase is the highest. Failure rate in this phase is the highest as the sample size and study design requires complex dosing at an optimum level.
Based on product and services, storage and distribution is expected to be the fastest growing segment owing to rising number of outsourced storage and distribution facility. Supply chain management is expected to dominate the market due to rising pressure to curb R&D cost and advancement in technology. Cold chain distribution is expected to witness the fastest growth due to rising number of biologics and temperature sensitive drugs while non-cold chain distribution is expected to dominate this segment over the forecast period.
As of 2016, supply chain management forms the largest segment with all the industry players paying high emphasis on maintaining experienced personnel clinical trial supply managers. This scenario is true for most of the regions across the globe, except in the U.S., wherein manufacturing is also expected to gain momentum at a lucrative rate. Over the forecast period, manufacturing is anticipated to witness the fastest growth at CAGR over 7.0%.
Biologics is expected to be the fastest growing segment based on end-use while pharmaceutical is expected to be the largest segment over the forecast period. The demand for biosimilar in both emerging and developed countries is also expected to fuel the growth of the industry.
Pharmaceuticals contributed to about 40.0% of the market share in 2016 and is expected to witness growth at a CAGR of 7.3% during the forecast period. Steady decrease in R&D pipeline for pharmaceutical drugs has been observed and it is being substituted by biological drugs, which is expected to impact the segment over the next eight years.
In terms of therapeutic area, oncology is expected to be the fastest growing and also the dominating segment owing to tremendous R&D pipeline of oncology drugs as majority of oncology drugs require temperature-sensitive distribution, which is further anticipated to fuel the growth of cold chain distribution.
Clinical trial supplies in oncology include primary and secondary packaging. The main objective of the packaging is to improve the patient compliance. Packaging must prevent the vials from leakage and other gases to aerosolize. The packaging should be done in accordance with the dosage. For instance, the hospitals in the U.S are disposing millions of cancer vials due to improper dosage, according to the United Press International. In 2016, Intensity Therapeutics Inc. funded USD 10 million towards clinical supplies for cancer-based research.
North America and Europe are the leading contributors to the global clinical trial supplies market owing to high share of clinical trials conducted in this region and greater number of clinical trial supply players with the most advanced technology. High cost of conducting clinical trial is expected to be the reason for relatively less growth compared to Asia pacific region.
Asia Pacific is expected to witness the fastest growth owing to its diverse population, easy access to patients, proximity to North America, and low translation cost. Latin America and MEA are also expected to witness significant growth owing to rise in number of clinical trials conducted in this region.
Key Players
KLIFO A/S, PAREXEL International Corporation, Almac Group Ltd, Movianto GmbH, Patheon Inc., Biocair International Ltd., PCI Services, Thermo Fischer Scientific, Sharp Packaging Services, and Catalent Pharma Solutions. Clinigen Group Plc, Merck Serono, and Chimerix.
Market Segmentation
- Clinical Phase Outlook
- Phase I
- Phase II
- Phase III
- Other
- Product & Services Outlook
- Manufacturing
- Storage & Distribution
- Cold chain distribution
- Non-cold chain
- Supply chain management
- End-Use Outlook
- Pharmaceutical
- Biologics
- Medical device
- Others
- Therapeutic Use Outlook
- Oncology
- CNS
- Cardiovascular
- Infectious disease
- Metabolic disorders
- Others
- Regional Outlook
- North America
- Europe
- Asia Pacific
- Latin America
- MEA
Click Here to View Full Report Table of Contents
Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/37892
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333